Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tirofiban group | Experimental | Intravenous tirofiban before endovascular thrombectomy |
|
| Placebo group | Placebo Comparator | Intravenous placebo before Endovascular Thrombectomy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravenous tirofiban before endovascular thrombectomy | Drug | The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients with functional independence (modified Rankin Scale [mRS] score of 0 to 2) | mRS ranges from 0-6, with high score meaning poor outcome | Day 90 |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients without disability (modified Rankin Scale [mRS] score of 0 to 1) or who returned to their premorbid mRS score at 90 days (for patients with prestroke mRS score >1) | mRS ranges from 0-6, with high score meaning poor outcome | Day 90 |
| ordinal distribution of modified Rankin Scale (mRS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hui-Sheng Chen | Contact | +86-024-28897511 | chszh@aliyun.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| General Hospital of Northern Theater Command | Recruiting | Shenyang | Liaoning | 110016 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intravenous placebo before endovascular thrombectomy | Drug | The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours. |
|
mRS ranges from 0-6, with high score meaning poor outcome |
| Day 90 |
| The proportions of patients with substantial reperfusion at initial preprocedure catheter angiogram (defined as mTICI score ≥2b) | Substantial reperfusion was defined as an expanded Thrombolysis In Cerebral Infarction grade of 2b50 (substantial reperfusion), 2c (nearcomplete reperfusion), or 3 (complete reperfusion). | immediately after first catheter angiogram |
| The proportions of patients with substantial reperfusion at final angiogram | immediately after final angiogram |
| The proportions of patients with complete recanalization as assessed by CTA or MRA 48 hours after endovascular treatment | 24 (-6/+24) hours |
| Change in National Institute of Health stroke scale (NIHSS) | NIHSS ranges from 0-42, with high score meaning poor outcome | 24 (-6/+24) hours |
| change in National Institute of Health stroke scale (NIHSS) | NIHSS ranges from 0-42, with high score meaning poor outcome | 7 (-2/+2) days |
| The incidence of symptomatic intracranial hemorrhage assessed according to Heidelberg bleeding classification | 24 (-6/+24) hours |
| The incidence of intraparenchymal hemorrhage (PH1 and PH2) | 24 (-6/+24) hours |
| The incidence of non-intracranial hemorrhage complications | 24 (-6/+24) hours |
| Serious adverse events | eg, acute respiratory failure, large or malignant middle cerebral artery infarction, acute heart failure, hemicraniectomy | 7 (-2/+2) days |
| Procedure-associated complications | Periprocedural |
| The proportion of patients with thrombocytopenia | 24 (-6/+24) hours |
| The incidence of mortality | Day 90 |
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided